

CITATION REPORT

List of articles citing

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500

DOI: 10.1200/jco.2014.56.2561

Journal of Clinical Oncology, 2014, 32, 3483-9.

Source: <https://exaly.com/paper-pdf/59490501/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
488	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. 2014 , 16, 440		77
487	Dynamic changes in numbers and properties of circulating tumor cells and their potential applications. <i>Cancers</i> , 2014 , 6, 2369-86	6.6	21
486	Solidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3470-1	2.2	19
485	The promise of circulating tumor cell analysis in cancer management. 2014 , 15, 448		38
484	Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?. 2014 , 25, 2304-2313		115
483	Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study). 2014 , 68, 32-40		16
482	Challenges in circulating tumour cell research. 2014 , 14, 623-31		923
481	Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. 2014 , 14, 456		81
480	Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 345-51	4.4	15
479	Molecular profiling of single circulating tumor cells with diagnostic intention. 2014 , 6, 1371-86		182
478	Circulating Tumor Cells: A Window Into Tumor Development and Therapeutic Effectiveness. 2015 , 22, 167-76		11
477	Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?. 2015 , 27, 560-7		28
476	Young investigator challenge: Application of cytologic techniques to circulating tumor cell specimens: Detecting activation of the oncogenic transcription factor STAT3. 2015 , 123, 696-706		10
475	Did circulating tumor cells tell us all they could? The missed circulating tumor cell message in breast cancer. 2015 , 30, e429-33		20
474	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. <i>PLoS ONE</i> , 2015 , 10, e0140712	3.7	442
473	Characterization of DNA Methylation in Circulating Tumor Cells. <i>Genes</i> , 2015 , 6, 1053-75	4.2	34
472	Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. <i>Clinical Cancer Research</i> , 2015 , 21, 2771-9	12.9	66

471	Using circulating tumor cells to guide therapy in breast cancer: could this replace biopsies?. 2015 , 16, 669-72		0
470	Tumor Marker Usage and Medical Care Costs Among Older Early-Stage Breast Cancer Survivors. 2015 , 26, 355-358		
469	Outcomes and endpoints in trials of cancer treatment: the past, present, and future. 2015 , 16, e32-42		111
468	Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment?. 2015 , 41, 144-50		57
467	Can circulating tumor cells predict resistance in metastatic breast cancer?. <i>Clinical Cancer Research</i> , 2015 , 21, 2421-3	12.9	9
466	Cytokeratin 20 improves the detection of circulating tumor cells in patients with colorectal cancer. 2015 , 358, 43-6		34
465	Clinical Significance of Circulating Tumor Cells in Peripheral Blood of Patients with Esophageal Squamous Cell Carcinoma. 2015 , 22, 3674-80		48
464	Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread. 2015 , 9, 733-45		79
463	Lessons for tumor biomarker trials: vicious cycles, scientific method & developing guidelines. 2015 , 15, 165-9		11
462	Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. <i>Current Oncology Reports</i> , 2015 , 17, 15	6.3	22
461	Circulating Tumour Cells as Liquid Biopsy in Breast Cancer: Advancing from Prognostic to Predictive Potential. 2015 , 7, 53-58		
460	Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity. <i>Frontiers in Oncology</i> , 2015 , 5, 42	5.3	55
459	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2695-704	2.2	214
458	Nanotechnology for enrichment and detection of circulating tumor cells. 2015 , 10, 1973-90		56
457	Development of a microfluidic-based optical sensing device for label-free detection of circulating tumor cells (CTCs) through their lactic acid metabolism. 2015 , 15, 6789-806		22
456	Using circulating tumor cells to inform on prostate cancer biology and clinical utility. 2015 , 52, 191-210		15
455	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015 , 33, 2623-31	2.2	31
454	Biomarkers in Breast Cancer: Where Are We and Where Are We Going?. 2015 , 71, 1-23		60

453	Clinical utility of circulating tumor cells in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1622	2.2	19
452	Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial. 2015 , 360, 213-8		35
451	Current and potential use of MAINTRAC method for cancer diagnosis and prediction of metastasis. 2015 , 15, 597-605		4
450	Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. 2015 , 17, 209-24		138
449	Mammakarzinom: Hohe CTC unter Chemotherapie sprechen für Resistenz. 2015 , 18, 33-33		
448	Validation of new cancer biomarkers: a position statement from the European group on tumor markers. 2015 , 61, 809-20		99
447	May CTC technologies promote better cancer management?. 2015 , 6, 1		21
446	Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). 2015 , 116, 17-29		14
445	Intratumoral Heterogeneity: From Diversity Comes Resistance. <i>Clinical Cancer Research</i> , 2015 , 21, 2916-23.9		95
444	Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer. 2015 , 75, 232-237		13
443	Thermoresponsive release of viable microfiltrated Circulating Tumor Cells (CTCs) for precision medicine applications. 2015 , 15, 4277-82		17
442	Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. <i>Clinical Cancer Research</i> , 2015 , 21, 4786-800	12.9	247
441	Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?. 2015 , 26, 1048-1057		38
440	Retrieval of Disseminated Tumor Cells Colonizing the Bone in Murine Breast Cancer Metastasis Models. 2015 , 20, 103-8		4
439	Circulating Tumor Cells, a Tremendous Prognostic Factor in Inflammatory Breast Cancer. 2015 , 107, djv281		3
438	Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 563-71	4.4	89
437	Expression profiling of circulating tumor cells in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 149, 121-31	4.4	40
436	Circulating tumor cell analysis in metastatic triple-negative breast cancers. <i>Clinical Cancer Research</i> , 2015 , 21, 1098-105	12.9	33

435	Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2487-98	12.9	102
434	Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. 2015 , 26, 510-6		38
433	Circulating Tumor Cells and Cancer Stem Cells: Clinical Implications in Nonmetastatic Breast Cancer.. 2016 , 10,		2
432	Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. <i>Oncotarget</i> , 2016 , 7, 66880-66891	3.3	48
431	Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. 2016 , 9, 7503-7513		26
430	Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers. <i>Oncotarget</i> , 2016 , 7, 26724-38	3.3	12
429	Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	50
428	Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence. <i>Frontiers in Oncology</i> , 2016 , 6, 255	5.3	28
427	Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	39
426	Circulating tumor cells in breast cancer patients. 2016 , 63, 18-29		8
425	Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer. 2016 , 13, 902-913		14
424	Pancreatic cancer: Are "liquid biopsies" ready for prime-time?. 2016 , 22, 7175-85		20
423	EMT: 2016. 2016 , 166, 21-45		2443
422	Reining in the Excessive Use of Medical Tests: What Are the Next Steps?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2807-9	2.2	
421	Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. 2016 , 16, 850		17
420	Nanoroughened adhesion-based capture of circulating tumor cells with heterogeneous expression and metastatic characteristics. 2016 , 16, 614		18
419	Current role of liquid biopsy in metastatic breast cancer and future perspectives. 2016 , 49, 680-684		
418	The promise of circulating tumor cells for precision cancer therapy. 2016 , 10, 1269-1285		10

417	Circulating Tumor Cells. 2016 , 219-234		
416	Biomarkers in the Clinic. 2016 , 415-426		
415	Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. 2016 , 33, 521-50		16
414	Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2820-6	2.2	22
413	The tumour trail left in blood. 2016 , 532, 269-71		66
412	Circulating tumor cells and circulating tumor DNA in colon cancer. 2016 , 9, 88-92		
411	Emerging Biomarkers of the Future: Changing Clinical Practice for 2020. 2016 , 8, 60-72		1
410	Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas. 2016 , 18, 44		27
409	CELLSEARCH [®] Instrument, Features, and Usage. 2016 , 377-400		
408	A Size-Selective Intracellular Delivery Platform. 2016 , 12, 5873-5881		18
407	Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. 2016 , 16, 1113-1120		5
406	Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 277-290	4.4	18
405	Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions. 2016 , 40, 117-129		1
404	Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 87-95	4.4	29
403	Yttrium-90 Radioembolization for Breast Cancer Liver Metastases. 2016 , 27, 1316-1319		12
402	Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. 2016 , 101, 4461-4467		29
401	Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes. 2016 , 33, 743-755		29
400	Circulating Tumor Cells and Historic Perspectives. 2016 , 1-32		

399	The pathway to clinical use of a cancer biomarker. 2016 , 245, S17-21		3
398	Is Breast Cancer a Curable Disease?. 2016 , 12, 13-6		4
397	Application of optically-induced-dielectrophoresis in microfluidic system for purification of circulating tumour cells for gene expression analysis- Cancer cell line model. 2016 , 6, 32851		49
396	Circulating tumor cells in breast cancer: applications in personalized medicine. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 411-424	4.4	35
395	Improving the CellSearch [®] system. 2016 , 16, 1291-1305		47
394	Capture and Release of Viable Circulating Tumor Cells from Blood. 2016 ,		1
393	Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. 2016 , 63, 97-104		36
392	Circulating tumor cell technologies. <i>Molecular Oncology</i> , 2016 , 10, 374-94	7.9	315
391	Circulating tumor cells in breast cancer. <i>Molecular Oncology</i> , 2016 , 10, 418-30	7.9	99
390	Curing Metastatic Breast Cancer. 2016 , 12, 6-10		46
389	Precision Microfilters as an all in one System for Multiplex Analysis of Circulating Tumor Cells. 2016 , 6, 6405-6414		23
388	Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 139-49	4.4	46
387	Review: circulating tumor cells in the practice of breast cancer oncology. <i>Clinical and Translational Oncology</i> , 2016 , 18, 749-59	3.6	5
386	HER2 imaging in the ZEPHIR study. 2016 , 27, 555-7		4
385	Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 882, 235-58	3.6	43
384	Novel Biomarkers in the Continuum of Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016 ,	3.6	9
383	In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis. 2016 , 18, 30		100
382	A novel approach for next-generation sequencing of circulating tumor cells. 2016 , 4, 395-406		19

381	Significance of Studying Circulating Tumor Cells. 2016 , 3-15		
380	Prognostic Implications of CTC in Breast Cancer. 2016 , 233-254		
379	CTC in Advanced Breast Cancer Prognosis, Monitoring, and Clinical Utility. 2016 , 257-270		
378	Evolution of Metastatic Disease: The Need for Monitoring and Emerging Therapeutic Opportunities. 2016 , 271-292		
377	Perspectives on Clinical Applications of CTCs. 2016 , 315-323		1
376	Tumor heterogeneity and circulating tumor cells. 2016 , 374, 216-23		50
375	Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer. 2016 , 12, 789-99		24
374	Genesis of Circulating Tumor Cells Through Epithelial-Mesenchymal Transition as a Mechanism for Distant Dissemination. 2016 , 139-182		2
373	Molecular Imaging of Biomarkers in Breast Cancer. 2016 , 57 Suppl 1, 53S-9S		44
372	Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NF- κ B-IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells. 2016 , 76, 2000-12		73
371	Circulating Tumor Cells. 2016 ,		4
370	Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets. 2016 , 142, 1883-95		17
369	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2016 , 34, 945-52	2.2	121
368	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. 2016 , 6, 479-91		840
367	Liquid Biopsy in Metastasized Breast Cancer as Basis for Treatment Decisions. <i>Oncology Research and Treatment</i> , 2016 , 39, 112-6	2.8	16
366	Using CTCs for pharmacogenomic analysis. 2016 , 106, 92-100		4
365	Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients. 2016 , 223, 20-9		30
364	Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma. 2016 , 47, 157-67		22

363	Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer. <i>Current Oncology Reports</i> , 2016 , 18, 3	6.3	19
362	Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 2583-93	12.9	222
361	Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution. 2016 , 16, 147-64		70
360	Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2016 , 18, 322-30	3.6	54
359	Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. 2016 , 293, 271-81		37
358	Breast Disease. 2016 ,		3
357	Circulating tumor cells in breast cancer--current status and perspectives. 2016 , 97, 22-9		28
356	Serum Tumor Marker Use in Patients With Advanced Solid Tumors. 2016 , 12, 65-6, e36-43		13
355	Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy. 2016 , 138, 1586-600		8
354	Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms. <i>Clinical Cancer Research</i> , 2016 , 22, 79-85	12.9	49
353	Progress of Circulating Tumor Cells in Cancer Management. 2016 , 15, 509-16		3
352	Circulating Tumor Cells: Fluid Surrogates of Solid Tumors. 2017 , 12, 419-447		62
351	Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients. 2017 , 32, 119-125		12
350	Enhanced Cell Capture on Functionalized Graphene Oxide Nanosheets through Oxygen Clustering. 2017 , 11, 1548-1558		42
349	Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. 2017 , 43, 1050-1055		45
348	Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?. 2017 , 41, 755-768		155
347	Circulating tumor cells: clinical validity and utility. 2017 , 22, 421-430		129
346	Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 162, 501-510	4.4	11

345	Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors. 2017 , 185, 58-84.e15		82
344	New applications of the acridine orange fluorescence staining method: Screening for circulating tumor cells. 2017 , 13, 2221-2229		8
343	Characterization of single circulating tumor cells. 2017 , 591, 2241-2250		36
342	How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case. <i>Seminars in Cancer Biology</i> , 2017 , 44, 106-116	12.7	32
341	Mechanisms of Molecular Carcinogenesis IVolume 2. 2017 ,		1
340	Potential and Challenges of Liquid Biopsies. 2017 , 233-261		
339	Materials and microfluidics: enabling the efficient isolation and analysis of circulating tumour cells. 2017 , 46, 4245-4280		101
338	Medical Ethics, Prediction, and Prognosis. 2017 ,		1
337	Isolation and Molecular Characterization of Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2017 ,	3.6	2
336	Flow Cytometric Methods for Circulating Tumor Cell Isolation and Molecular Analysis. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 994, 105-118	3.6	2
335	Circulating Tumor Cells as Cancer Biomarkers in the Clinic. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 994, 1-41	3.6	17
334	Enrichment, Isolation and Molecular Characterization of EpCAM-Negative Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 994, 181-203	3.6	14
333	Strategies for Isolation and Molecular Profiling of Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 994, 43-66	3.6	2
332	Biopsie liquide : cellules tumorales circulantes et radiothérapie. <i>Oncologie</i> , 2017 , 19, 71-76	1	1
331	Drug-biomarker co-development in oncology - 20 years and counting. 2017 , 30, 48-62		38
330	Clinical Applications of Circulating Tumor Cells in Pharmacotherapy: Challenges and Perspectives. 2017 , 92, 232-239		9
329	Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis. 2017 , 7, 43464		67
328	Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms. 2017 , 24, R223-R237		26

327	Enumeration and Molecular Analysis of CTCs in Metastatic Disease: The Breast Cancer Model. 2017 , 41-65		
326	Identification and Quantitation of Circulating Tumor Cells. 2017 , 10, 321-343		38
325	Classifying circulating tumor cells to monitor cancer progression. 2017 , 17, 153-165		7
324	Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. 2017 , 28, 468-477		41
323	Molecular Classification and Testing of Breast Carcinoma. 2017 , 215-231		
322	The Landscape of Circulating Tumor Cell Research in the Context of Epithelial-Mesenchymal Transition. 2017 , 84, 264-283		9
321	Microfilter-Based Capture and Release of Viable Circulating Tumor Cells. 2017 , 1634, 93-105		3
320	Biological and Molecular Characterization of Circulating Tumor Cells: A Creative Strategy for Precision Medicine?. 2017 , 82, 71-103		1
319	Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring. 2017 , 474, 3269-3306		44
318	Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review. 2017 , 17, 939-949		5
317	RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. 2017 , 83, 185-193		17
316	Molecular analysis of single circulating tumour cells following long-term storage of clinical samples. <i>Molecular Oncology</i> , 2017 , 11, 1687-1697	7.9	9
315	Molecular characterization and heterogeneity of circulating tumor cells in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 695-700	4.4	23
314	Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. 2017 , 15, 316-324		2
313	In vitro selections of mammaglobin A and mammaglobin B aptamers for the recognition of circulating breast tumor cells. 2017 , 7, 14487		20
312	One-Step Systemic Staging for Patients with Breast Cancer. 2017 , 265-276		
311	Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer. <i>Oncology Research and Treatment</i> , 2017 , 40, 409-416	2.8	23
310	Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 165, 733-741	4.4	19

309	Circulating Tumor Cells in Advanced Prostate Cancer: Time to Move from Prognostic to Predictive Ability. <i>European Urology</i> , 2017 , 71, 172-173	10.2	4
308	Improving sensitivity and specificity of capturing and detecting targeted cancer cells with anti-biofouling polymer coated magnetic iron oxide nanoparticles. 2017 , 150, 261-270		30
307	Applications of DNA-Based Liquid Biopsy for Central Nervous System Neoplasms. 2017 , 19, 24-34		43
306	Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 83-94	4.4	112
305	Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?. 2017 , 14, 32-44		102
304	Molecular heterogeneity in breast cancer: State of the science and implications for patient care. 2017 , 64, 65-72		115
303	Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 751-758	2.2	71
302	Breast Pathology. 2017 ,		1
301	Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?. 2017 , 77, 1291-1298		14
300	Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer.. 2017 , 1, 1-12		3
299	Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies. 2017 , 37, 358-369		3
298	Monitoring for Response to Antineoplastic Drugs: The Potential of a Metabolomic Approach. 2017 , 7,		7
297	Gold Nanoparticle Based Platforms for Circulating Cancer Marker Detection. 2017 , 1, 80-102		41
296	Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	31
295	Tumor Heterogeneity in Breast Cancer. 2017 , 4, 227		211
294	Androgen receptor expression on circulating tumor cells in metastatic breast cancer. <i>PLoS ONE</i> , 2017 , 12, e0185231	3.7	17
293	Addressing the challenges of applying precision oncology. 2017 , 1, 28		19
292	Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration. <i>Oncotarget</i> , 2017 , 8, 109818-109835	3.3	4

291	Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion. <i>Oncotarget</i> , 2017 , 8, 1884-1912	3.3	46
290	Pathway of peritoneal carcinomatosis maybe hematogenous metastasis rather than peritoneal seeding. <i>Oncotarget</i> , 2017 , 8, 41549-41554	3.3	8
289	Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients. <i>Oncotarget</i> , 2017 , 8, 34884-34895	3.3	29
288	Biophysical technologies for understanding circulating tumor cell biology and metastasis. 2017 , 6, 473-485		9
287	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. 2018 , 40, 45-52		4
286	Clinical indications for, and the future of, circulating tumor cells. 2018 , 125, 143-150		33
285	Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Epirubicin Pegol. <i>Clinical Cancer Research</i> , 2018 , 24, 3348-3357	12.9	15
284	Clinical utility of non-EpCAM based circulating tumor cell assays. 2018 , 125, 132-142		16
283	Clinical applications of the CellSearch platform in cancer patients. 2018 , 125, 102-121		118
282	Immune gene expression and response to chemotherapy in advanced breast cancer. 2018 , 118, 480-488		20
281	Assessment and Designation of Breast Cancer Stage. 2018 , 531-552.e6		2
280	Detection and Clinical Implications of Occult Systemic Micrometastatic Breast Cancer. 2018 , 858-866.e3		0
279	Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration. 2018 , 125, 122-131		10
278	Microfluidic Devices for the Isolation of Circulating Tumor Cells (CTCs). 2018 , 237-260		
277	Circulating Tumors Cells as a Biomarker of Radiation Benefit. 2018 , 4, e180194		3
276	Circulating tumor cells (CTCs) and cytokeratin 19 (CK19) mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancer. 2018 , 16, 13-17		2
275	Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges. 2018 , 24, 61-64		9
274	Circulating Tumor Cells: Diagnostic and Therapeutic Applications. 2018 , 20, 329-352		51

273	Functional Diagnostic and Therapeutic Nanoconstructs for Efficient Probing of Circulating Tumor Cells. 2018 , 10, 14231-14247		11
272	Circulating tumor cell isolation, culture, and downstream molecular analysis. 2018 , 36, 1063-1078		98
271	Development and Application of Liquid Biopsies in Metastatic Prostate Cancer. <i>Current Oncology Reports</i> , 2018 , 20, 35	6.3	19
270	Prognostic and predictive biomarkers in breast cancer: Past, present and future. <i>Seminars in Cancer Biology</i> , 2018 , 52, 56-73	12.7	182
269	Molecular characterization of circulating tumor cells-from bench to bedside. 2018 , 75, 88-97		27
268	Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. 2018 , 78, 1110-1122		60
267	Liquid biopsies in gastrointestinal malignancies: when is the big day?. 2018 , 18, 19-38		20
266	Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2710-2717	4.0	
265	Evaluating the Potential Benefits of Using Sustained Response as a Prognostic Factor in Intermediate Hepatocellular Carcinoma Following Treatment With Conventional Chemoembolization. 2018 , 1, e183209		
264	Zirkulierende Tumorzellen, zirkulierende Tumor-DNA und zirkulierende microRNA beim metastasierten Mammakarzinom [Übersicht]: Welche Rolle spielt die Liquid Biopsy beim Brustkrebs?. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2018 , 15, 23-30	0	
263	Gene expression signatures in circulating tumor cells correlate with response to therapy in metastatic breast cancer. 2018 , 3, 33-33		
262	Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. 2018 , 20, 230-237		8
261	Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows-Venous Whole Blood and Plasma. 2018 , 6, 275-286		42
260	Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. 2018 , 20, 48		53
259	Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. 2018 , 13, 1625-1637		7
258	ASO Author Reflections: The Whole Transcriptome Landscape of Circulating Tumor Cells in Nonmetastatic Breast Cancer. 2018 , 25, 646-647		
257	Circulating Tumor Cells and Circulating Tumor DNA. 2018 , 235-281		6
256	Circulating Tumor Cells: Applications in Cytopathology. 2018 , 11, 679-686		8

255	Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. 2018 , 10, 1758835918794630	202
254	The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value. 2018 , 45, 2025-2035	6
253	Circulating tumor cells as biomarkers in head and neck cancer: recent advances and future outlook. 2018 , 18, 897-906	11
252	Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition. 2018 , 83, 121-181	18
251	Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA. 2018 , 40, 1010428318776169	39
250	The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma. 2018 , 57, 2695-2700	5
249	Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. 2018 , 14, e1801131	71
248	ClearCell [®] FX, a label-free microfluidics technology for enrichment of viable circulating tumor cells. 2018 , 93, 1251-1254	46
247	Health economic impact of liquid biopsies in cancer management. 2018 , 18, 593-599	18
246	Gelatin Nanoparticle-Coated Silicon Beads for Density-Selective Capture and Release of Heterogeneous Circulating Tumor Cells with High Purity. 2018 , 8, 1624-1635	45
245	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. 2018 , 4, 1700-1706	101
244	Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer. 2018 , 5, 9	70
243	Autoantibodies as Potential Biomarkers in Breast Cancer. 2018 , 8,	24
242	The viable circulating tumor cells with cancer stem cells feature, where is the way out?. 2018 , 37, 38	26
241	Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy. 2018 , 18, e1077-e1085	4
240	Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study. 2018 , 268, 408-420	73
239	A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. 2018 , 8, 1286-1299	58
238	Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. <i>Clinical Cancer Research</i> , 2018 , 24, 5860-5872 ^{12,9}	31

237	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. 2019 , 11, 1758835919866065		17
236	Circulating Hybrid Cells Join the Fray of Circulating Cellular Biomarkers. 2019 , 8, 595-607		10
235	Liquid biopsy for the detection and management of surgically resectable tumors. 2019 , 404, 517-525		2
234	CTC analysis: an update on technological progress. 2019 , 212, 14-25		10
233	A Novel Peptide Probe for Identification of PLS3-Expressed Cancer Cells. 2019 , 91, 9640-9647		5
232	Current status of liquid biopsies for the detection and management of prostate cancer. 2019 , 11, 5271-5291		33
231	EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. 2019 , 117, 60-68		43
230	Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. 2019 , 21, 802-809		19
229	CANCER BIOMARKERS. 2019 , 107-121		
228	Liquid Biopsy for Hepatocellular Carcinoma. 2019 , 18, 390-399		1
227	Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions. 2019 , 8,		28
226	Current progress in the clinical use of circulating tumor cells as prognostic biomarkers. 2019 , 127, 739-749		15
225	Breast Cancer Heterogeneity in Primary and Metastatic Disease. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1152, 75-104	3.6	13
224	The current status of the clinical utility of liquid biopsies in cancer. 2019 , 19, 1031-1041		11
223	Panoptic View of Prognostic Models for Personalized Breast Cancer Management. <i>Cancers</i> , 2019 , 11,	6.6	4
222	A Novel Panel of 80 RNA Biomarkers with Differential Expression in Multiple Human Solid Tumors against Healthy Blood Samples. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	2
221	Profiling of Invasive Breast Carcinoma Circulating Tumour Cells-Are We Ready for the 'Liquid' Revolution?. <i>Cancers</i> , 2019 , 11,	6.6	8
220	Microfluidic device for circulating tumor cell quantification and capture. 2019 ,		

219	Novel approaches in cancer management with circulating tumor cell clusters. 2019 , 4, 1-18		24
218	Circulating Tumor Cells Develop Resistance to TRAIL-Induced Apoptosis Through Autophagic Removal of Death Receptor 5: Evidence from an In Vitro Model. <i>Cancers</i> , 2019 , 11,	6.6	17
217	Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities. 2019 , 24, 1715-1719		7
216	Human-specific RNA analysis shows uncoupled epithelial-mesenchymal plasticity in circulating and disseminated tumour cells from human breast cancer xenografts. 2019 , 36, 393-409		10
215	Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine. 2019 , 79, 2798-2804		83
214	The biology and clinical potential of circulating tumor cells. 2019 , 53, 131-147		31
213	Fugitives on the run: circulating tumor cells (CTCs) in metastatic diseases. 2019 , 38, 297-305		15
212	Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer. 2019 , 11, 52-66		1
211	Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients. 2019 , 145, 2873-2883		23
210	The Significance of Circulating Tumour Cells in the Clinic. 2019 , 63, 466-478		9
209	Liquid Biopsy in Solid Malignancy. 2019 , 23, 284-296		10
208	Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. 2019 , 30, 945-952		53
207	Circulating and Disseminated Tumour Cells in Breast Carcinoma: Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018. 2019 , 79, 177-183		5
206	Breast Disease. 2019 ,		
205	A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. 2019 , 10, 1478		45
204	Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. 2019 , 25, 219-225		6
203	Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. <i>Clinical Cancer Research</i> , 2019 , 25, 6089-6097	12.9	27
202	CTCs as Liquid Biopsy: Where Are We Now?. 2019 ,		1

201	Zirkulierende Tumorzellen, zirkulierende Tumor-DNA und zirkulierende microRNA beim metastasierten Mammakarzinom [Übersicht]: Welche Rolle spielt die Liquid Biopsy beim Brustkrebs?. 2019 , 51, 65-73	
200	. 2019 ,	7
199	Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer. 2019 , 9, 17276	12
198	First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial. 2019 , 11, 10427-10433	2
197	Advanced liquid biopsy technologies for circulating biomarker detection. 2019 , 7, 6670-6704	74
196	Circulating and Disseminated Tumor Cells in Breast Carcinoma: Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019. 2019 , 79, 1320-1327	12
195	Are liquid biopsies ready for primetime?. 2019 , 125, 834-837	2
194	Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. 2019 , 19, e283-e296	15
193	Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. 2019 , 106, 133-143	20
192	Circulating tumor cells in metastatic breast cancer: clinical relevance and biological potential. 2019 , 31, 76-81	1
191	Head and Neck Squamous Cell Carcinoma Detection and Surveillance: Advances of Liquid Biomarkers. 2019 , 129, 1836-1843	12
190	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. 2019 , 134, 39-45	129
189	Role of Circulating Tumor Cells in Breast Cancer Patients. 2019 , 383-392	
188	Prognostic and Predictive Role of Circulating Tumor Cells. 2019 , 181-190	0
187	The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. 2019 , 39, 1	50
186	Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?. 2019 , 111, 339-341	7
185	Detection of Predictive Biomarkers Using Liquid Biopsies. 2019 , 107-117	1
184	Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. 2019 , 111, 380-387	55

183	Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 173, 155-165	4.4	6
182	Integration of rare cell capture technology into cytologic evaluation of cerebrospinal fluid specimens from patients with solid tumors and suspected leptomeningeal metastasis. 2020 , 9, 45-54		4
181	Tumor Liquid Biopsies. <i>Recent Results in Cancer Research</i> , 2020 ,	1.5	5
180	Cancer of the Breast. 2020 , 1560-1603.e12		6
179	Microfluidics as an Enabling Technology for Personalized Cancer Therapy. 2020 , 16, e1904321		26
178	Association of Serum Progranulin Levels With Disease Progression, Therapy Response and Survival in Patients With Metastatic Breast Cancer. 2020 , 20, 220-227		9
177	Magnetic Cell Centrifuge Platform Performance Study with Different Microsieve Pore Geometries. 2019 , 20,		5
176	Recent advances in microfluidic technologies for circulating tumor cells: enrichment, single-cell analysis, and liquid biopsy for clinical applications. 2020 , 20, 3854-3875		31
175	Cellular Mechanisms of Circulating Tumor Cells During Breast Cancer Metastasis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	15
174	Liquid Biopsy in Breast Cancer. 2020 , 80, 1093-1104		2
173	Mesenchymal Characteristics and Predictive Biomarkers on Circulating Tumor Cells for Therapeutic Strategy. <i>Cancers</i> , 2020 , 12,	6.6	3
172	Short-Term Circulating Tumor Cell Dynamics in Mouse Xenograft Models and Implications for Liquid Biopsy. <i>Frontiers in Oncology</i> , 2020 , 10, 601085	5.3	7
171	Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities. <i>Cancers</i> , 2020 , 12,	6.6	42
170	Injectable In Situ Self-Cross-Linking Hydrogels Based on Hemoglobin, Carbon Quantum Dots, and Sodium Alginate for Real-Time Detection of Wound Bacterial Infection and Efficient Postoperative Prevention of Tumor Recurrence. 2020 , 36, 13263-13273		10
169	Liquid Biopsy to Detect Circulating Tumor Cells: Is It Ready for a Value Proposition in Laboratory Medicine?. 2020 , 5, 1027-1037		1
168	Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). 2020 , 19, 2363-2370		7
167	Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients. <i>PLoS ONE</i> , 2020 , 15, e0237308	3.7	18
166	Clinical relevance of in breast cancer: update in 2020. 2020 , 20, 913-919		5

165	Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients. <i>Cancers</i> , 2020 , 12,	6.6	2
164	Zirkulierende und disseminierte Tumorzellen beim Mammakarzinom. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2020 , 17, 121-128	0	
163	The Utility of Liquid Biopsies in Radiation Oncology. 2020 , 107, 873-886		8
162	Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume. 2020 , 20, 440		8
161	Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma. 2020 , 123, 114-125		7
160	Liquid Biopsy Strategies to Distinguish Progression from Pseudoprogression and Radiation Necrosis in Glioblastomas. 2020 , 4, e2000029		7
159	[Liquid biopsy for cancer diagnosis: the potential of exosomes and circulating miRNAs]. 2020 , 57, 99-108		
158	Liquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	7
157	Enumeration and molecular characterization of circulating tumor cells as an innovative tool for companion diagnostics in breast cancer. 2020 , 20, 815-828		2
156	Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patients. 2020 , 147, 3550-3559		10
155	Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities. 2020 , 10, 3311		3
154	Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation?. 2020 , 37, 29		14
153	Klinischer Stellenwert der Liquid biopsy beim Mammakarzinom. 2020 , 26, 736-745		
152	Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer. 2020 , 301, 1027-1035		11
151	Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	16
150	Circulating tumor cells: moving forward into clinical applications. 2020 , 3, 4-4		9
149	Non-coding RNAs and nuclear architecture during epithelial-mesenchymal transition in lung cancer and idiopathic pulmonary fibrosis. 2020 , 70, 109593		10
148	2. Therapie des metastasierten Mammakarzinoms. 2020 , 71-120		

147	Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	23
146	Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. 2020 , 6, 1410-1415		66
145	EMT-Associated Heterogeneity in Circulating Tumor Cells: Sticky Friends on the Road to Metastasis. <i>Cancers</i> , 2020 , 12,	6.6	34
144	Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. <i>Clinical Cancer Research</i> , 2020 , 26, 4911-4920	12.9	4
143	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. 2020 , 16, 2059-2073		1
142	In Vivo Detection of CTC and CTC Plakoglobin Status Helps Predict Prognosis in Patients with Metastatic Breast Cancer. 2020 , 26, 2435-2442		5
141	Dynamic changes of Receptor activator of nuclear factor- κ B expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer. 2020 , 10, 1288		12
140	Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. 2020 , 18, 2879-2902.e9		18
139	Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	8
138	Microfluidics and Nanomaterial-based Technologies for Circulating Tumor Cell Isolation and Detection. 2020 , 20,		6
137	Gauging the Impact of Cancer Treatment Modalities on Circulating Tumor Cells (CTCs). <i>Cancers</i> , 2020 , 12,	6.6	4
136	Evolution of Estrogen Receptor Status from Primary Tumors to Metastasis and Serially Collected Circulating Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
135	EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream [®] in patients with breast cancer treated with primary systemic therapy. <i>PLoS ONE</i> , 2020 , 15, e0229903	3.7	11
134	Facile synthesis of 3D hierarchical micro-/nanostructures in capillaries for efficient capture of circulating tumor cells. 2020 , 575, 108-118		4
133	53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients. <i>Cancers</i> , 2020 , 12,	6.6	2
132	Circulating Tumor Cells in Breast Cancer Metastatic Disease. <i>Advances in Experimental Medicine and Biology</i> , 2020 ,	3.6	1
131	Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 455-463	4.4	3
130	Evaluating the Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer-Is Not Worse Good Enough?. 2021 , 7, 30-31		1

129	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. 2021 , 113, 443-452		8
128	Clinical utility of circulating tumor cells: an update. <i>Molecular Oncology</i> , 2021 , 15, 1647-1666	7.9	28
127	Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations. 2021 , 325, 36-38		7
126	Circulating Tumor Marker Isolation with the Chemically Stable and Instantly Degradable (CSID) Hydrogel Immunospheres. 2021 , 93, 1100-1109		2
125	The Role of Circulating Tumor Cells in Breast Cancer and Implications for Radiation Treatment Decisions. 2021 , 109, 44-59		4
124	Liquid biopsy enters the clinic - implementation issues and future challenges. 2021 , 18, 297-312		158
123	Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane. 2021 , 87, 277-287		3
122	Liquid Biopsy in Breast Cancer: Circulating Tumor Cells and Circulating Tumor DNA. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1187, 337-361	3.6	1
121	Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy. 2021 , 13, 17588359211028492		4
120	Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. 2021 , 11,		8
119	Circulating tumor cells can predict the prognosis of patients with non-small cell lung cancer after resection: a retrospective study. 2021 , 10, 995-1006		6
118	Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA. 2021 , 22, 21		2
117	Circulating tumor cell profiling for precision oncology. <i>Molecular Oncology</i> , 2021 , 15, 1622-1646	7.9	8
116	Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. 2021 , 59, 1181-1200		22
115	Relevance of Circulating Hybrid Cells as a Non-Invasive Biomarker for Myriad Solid Tumors.		1
114	Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. 2021 , 18, 454-467		4
113	Breast Cancer Brain Metastasis-Overview of Disease State, Treatment Options and Future Perspectives. <i>Cancers</i> , 2021 , 13,	6.6	7
112	Liquid Biopsy: From Discovery to Clinical Application. 2021 , 11, 858-873		86

111	A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients. <i>Cancers</i> , 2021 , 13,	6.6	1
110	Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice. <i>Cancers</i> , 2021 , 13,	6.6	5
109	Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer. 2021 , 5, 943-952		1
108	Liquid Biopsy beim Mammakarzinom. 2021 , 42, 361-372		
107	Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. 2021 , 7, 77		7
106	Identification and characterization of effusion tumor cells (ETCs) from remnant pleural effusion specimens. 2021 , 129, 893-906		1
105	Functional Genomic Analysis of Breast Cancer Metastasis: Implications for Diagnosis and Therapy. <i>Cancers</i> , 2021 , 13,	6.6	4
104	Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer. 2021 , 11, 13441		3
103	Post San Antonio update by top three abstracts!. 2021 , 14, 244-246		0
102	Isolation of Circulating Biomarkers for Liquid Biopsy using Immunoaffinity-Based Stimuli-Responsive Hybrid Hydrogel Beads. 2021 , 1, 117-129		1
101	Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors. 2021 , 11, 13630		8
100	Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 698551	5.3	3
99	Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects. 2021 , 21, 1037-1048		2
98	Elevated mRNA Level of Y-Box Binding Protein 1 Indicates Unfavorable Prognosis Correlated with Macrophage Infiltration and T Cell Exhaustion in Luminal Breast Cancer. 2021 , 13, 6411-6428		1
97	Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer. 2021 , 7, 115		9
96	Technical Challenges for CTC Implementation in Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
95	Evaluation of the Safety and Feasibility of Apheresis in Dogs: For Application in Metastatic Cancer Research. 2021 , 11,		0
94	Circulating Biomarkers in Breast Cancer. 2021 ,		5

93	Role of Phenotypes of Circulating Tumor Cells in the Diagnosis and Treatment of Colorectal Cancer. 2021 , 13, 7077-7085		2
92	Prognostic impact and potential predictive role of baseline circulating tumor cells in locally advanced head and neck squamous cell carcinoma. 2021 , 121, 105480		2
91	Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial. 2021 , 124, 1207-1213		5
90	Liquid Biopsy: Application in Early Diagnosis and Monitoring of Cancer. 2020 , 1, 2000063		11
89	Liquid Biopsy: Translating Minimally Invasive Disease Profiling from the Lab to the Clinic. 2019 , 145-167		1
88	Genetic Analysis of Circulating Tumour Cells. <i>Recent Results in Cancer Research</i> , 2020 , 215, 57-76	1.5	6
87	Circulating Tumor Cells in Breast Cancer. <i>Recent Results in Cancer Research</i> , 2020 , 215, 127-145	1.5	5
86	Clinical Applications of Circulating Tumor Cells in Breast Cancer. <i>Recent Results in Cancer Research</i> , 2020 , 215, 147-160	1.5	4
85	HER2-targeted therapy influences CTC status in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 182, 127-136	4.4	12
84	Short-term circulating tumor cell dynamics in mouse xenograft models and implications for liquid biopsy.		3
83	Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. <i>PLoS Medicine</i> , 2016 , 13, e1002198	11.6	151
82	Antigen-agnostic microfluidics-based circulating tumor cell enrichment and downstream molecular characterization. <i>PLoS ONE</i> , 2020 , 15, e0241123	3.7	7
81	Molecular characterization of circulating colorectal tumor cells defines genetic signatures for individualized cancer care. <i>Oncotarget</i> , 2017 , 8, 68026-68037	3.3	15
80	Size-based detection of sarcoma circulating tumor cells and cell clusters. <i>Oncotarget</i> , 2017 , 8, 78965-78973	3.3	28
79	Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. <i>Oncotarget</i> , 2016 , 7, 41677-41690	3.3	30
78	Place des CTC et de l'ADN circulant dans la prise en charge du cancer du sein. <i>Oncologie</i> , 2019 , 21, 40-48	1	1
77	Circulating tumor cells isolation: the "post-EpCAM era". <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015 , 27, 461-70	3.8	11
76	Cancer biomarker discovery and validation. <i>Translational Cancer Research</i> , 2015 , 4, 256-269	0.3	259

75	CTC enumeration and characterization: moving toward personalized medicine. <i>Annals of Translational Medicine</i> , 2014 , 2, 108	3.2	64
74	Comparison of hormonal receptor expression and HER2 status between circulating tumor cells and breast cancer metastases. <i>Clinics</i> , 2021 , 76, e2971	2.3	0
73	The Presence of Circulating Tumor Cell Cluster Characterizes an Aggressive Hepatocellular Carcinoma Subtype. <i>Frontiers in Oncology</i> , 2021 , 11, 734564	5.3	0
72	Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. <i>Cancers</i> , 2021 , 13,	6.6	1
71	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2021 , 81, 37-37	10.2	3
70	Metastatic Breast Cancer. 2016 , 451-474		
69	Bone Marrow Micrometastases and Circulating Tumor Cells. 2016 , 229-239		
68	Translation of Biomarkers into Clinical Practice. 2016 , 1-18		
67	Liquid Biopsy in Breast Carcinoma. 2019 , 247-252		
66	Liquid biopsy in metastatic breast cancer.. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019 , 2, 1062-1068	4.5	
65	Bone Marrow Micrometastases and Circulating Tumor Cells. 2019 , 191-199		1
64	Biopsia líquida: una review. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2019 , 15,	1.1	
63	Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA. <i>Oncology Research and Treatment</i> , 2021 ,	2.8	0
62	MiR-146a Regulates Migration and Invasion by Targeting NRP2 in Circulating-Tumor Cell Mimicking Suspension Cells. <i>Genes</i> , 2020 , 12,	4.2	1
61	Clinical Relevance and Therapeutic Application of CTCs in Advanced Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1220, 147-164	3.6	0
60	Circulating Tumor Cells as Biomarkers in Pancreatic Cancer. <i>Molecular and Translational Medicine</i> , 2020 , 129-143	0.4	
59	Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.		
58	Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design. <i>Pharmaceutics</i> , 2021 , 13,	6.4	3

57	The potential for liquid biopsies in the precision medical treatment of breast cancer. <i>Cancer Biology and Medicine</i> , 2016 , 13, 19-40	5.2	10
56	Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?. <i>American Journal of Translational Research (discontinued)</i> , 2017 , 9, 2807-2823	3	10
55	Two Novel Compounds with Tri-aryl Structures as Effective Anti-Breast Cancer Candidates. <i>Iranian Journal of Pharmaceutical Research</i> , 2020 , 19, 145-152	1.1	
54	A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222. <i>Clinical Cancer Research</i> , 2021 ,	12.9	
53	PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. <i>PLoS ONE</i> , 2021 , 16, e0260124	3.7	4
52	Multiparametric Circulating Tumor Cell Analysis to Select Targeted Therapies for Breast Cancer Patients. <i>Cancers</i> , 2021 , 13,	6.6	0
51	Circulating tumor cells: biology and clinical significance. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 404	21	34
50	Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse.. <i>Pharmaceuticals</i> , 2022 , 15,	5.2	2
49	A review of prognostic and predictive biomarkers in breast cancer.. <i>Clinical and Experimental Medicine</i> , 2022 , 1	4.9	3
48	Application of Circulating Tumor Cells in Peripheral Blood in Judging the Prognosis of Patients with Renal Cancer and Related Indexes of Blood Coagulation. <i>Open Journal of Urology</i> , 2022 , 12, 1-6	0.2	
47	Circulating Tumour DNA in Melanoma-Clinic Ready?. <i>Current Oncology Reports</i> , 2022 , 24, 363	6.3	1
46	Review of imaging techniques for evaluating morphological and functional responses to the treatment of bone metastases in prostate and breast cancer.. <i>Clinical and Translational Oncology</i> , 2022 , 1	3.6	1
45	Liquid Biopsy beim Mammakarzinom. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021 , 18, 365-376	0	
44	Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. <i>ESMO Open</i> , 2021 , 6, 100299	6	3
43	Role of circulating tumor DNA and circulating tumor cells in breast cancer: History and updates.. <i>SAGE Open Medicine</i> , 2022 , 10, 20503121221077838	2.4	0
42	Clinical Validation of a Circulating Tumor Cell Assay Using Density Centrifugation and Automated Immunofluorescence Microscopy.. <i>American Journal of Clinical Pathology</i> , 2022 ,	1.9	0
41	Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker.. <i>Cancers</i> , 2022 , 14,	6.6	0
40	The Role of Circulating Tumor Cells in the Prognosis of Metastatic Triple-Negative Breast Cancers: A Systematic Review of the Literature.. <i>Biomedicines</i> , 2022 , 10,	4.8	0

39	Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments.. <i>Molecular Cancer</i> , 2022 , 21, 79	42.1	15
38	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.. <i>Oncologist</i> , 2022 ,	5.7	4
37	Signal and Measurement Considerations for Human Translation of Diffuse in vivo Flow Cytometry.		0
36	Chemokines in Triple-Negative Breast Cancer Heterogeneity: New Challenges for Clinical Implications.. <i>Seminars in Cancer Biology</i> , 2022 ,	12.7	7
35	Circulating tumor cells in precision medicine: challenges and opportunities.. <i>Trends in Pharmacological Sciences</i> , 2022 ,	13.2	4
34	Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection. <i>Molecular Oncology</i> , 2021 ,	7.9	1
33	DataSheet_1.pdf. 2020 ,		
32	Prospects for Fluorescence Molecular In Vivo Liquid Biopsy of Circulating Tumor Cells in Humans. 2022 , 3,		1
31	Utility of Personalized Medicine in the Treatment of Different Subtypes of Breast Cancer. 2022 , 337-366		
30	Circulating tumor DNA: current challenges for clinical utility. <i>Journal of Clinical Investigation</i> , 2022 , 132,	15.9	1
29	Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> ,	2.2	2
28	Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 7843	6.3	0
27	Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis? Results from the Adjuvant SUCCESS A Trial. 2022 , 14, 3949		2
26	Circulating Cells with Macrophage-like Characteristics in Cancer: The Importance of Circulating Neoplastic-Immune Hybrid Cells in Cancer. 2022 , 14, 3871		2
25	Bioplatfoms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications. 1-45		2
24	Mitochondria dysfunction in circulating tumor cells. 12,		
23	Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment. 2022 , 23, 9535		1
22	Electrospun nanofibers for 3-D cancer models, diagnostics, and therapy.		0

21	Circulating Tumor-Derived Endothelial Cells: An Effective Biomarker for Breast Cancer Screening and Prognosis Prediction. 2022 , 2022, 1-11	0
20	Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer. 2022 , 8,	0
19	Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab.	1
18	Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. 2022 ,	2
17	Impact of changing treatment strategy based on circulating tumor cells on postoperative survival of breast cancer. 12,	0
16	Clinical Relevancy of Circulating Tumor Cells in Breast Cancer: Epithelial or Mesenchymal Characteristics, Single Cells or Clusters?. 2022 , 23, 12141	1
15	The Present and Future of Clinical Management in Metastatic Breast Cancer. 2022 , 11, 5891	0
14	A Novel Detection Method of Breast Cancer through a Simple Panel of Biomarkers. 2022 , 23, 11983	0
13	Circulating Tumor Cells and Breast Cancer Metastasis: From Enumeration to Somatic Mutational Profile. 2022 , 11, 6067	0
12	Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes. 2022 , 14, 5668	1
11	Chondroitin Sulfate Targeting Nanodrug Achieves Near-Infrared Fluorescence-Guided Chemotherapy Against Triple-Negative Breast Primary and Lung Metastatic Cancer. Volume 17, 5547-5563	1
10	Biology, vulnerabilities and clinical applications of circulating tumour cells.	1
9	Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer. 2023 ,	1
8	Circulating Tumor Cells in Breast Cancer. 2023 ,	0
7	Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. 2023 , 21, 181-209	1
6	Circulating tumour cells: The Good, the Bad and the Ugly. 2023 , 1878, 188863	0
5	Advances in early detection methods for solid tumors. 14,	0
4	Liquid Biopsies, Novel Approaches and Future Directions. 2023 , 15, 1579	0

- 3 Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients. **2023**, 15, 1616
- 2 Utilization of Circulating Tumor Cells in the Management of Solid Tumors. **2023**, 13, 694
- 1 Single-Cell Enzymatic Screening for Epithelial Mesenchymal Transition with an Ultrasensitive Superwetting Droplet-Array Microchip.